Neuroblastoma: contemporary management

Mullassery, Dhanya; Dominici, Carlo; Jesudason, Edwin C.; McDowell, Heather P.; Losty, Paul D.

doi:10.1136/adc.2008.143909

Cited by 28 publications

(29 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When defining the requirements for proper use of MIA in NB, it is necessary to consider recent advances in the understanding of this disease [41,42]. These advances include the determination of IDRFs and the better assessment of tumor biology.…”

Section: Nbmentioning

confidence: 99%

Minimally invasive adrenalectomy in children

Héloury

Muthucumaru

Panabokke

et al. 2012

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Section: Nbmentioning

confidence: 99%

Minimally invasive adrenalectomy in children

Héloury

Muthucumaru

Panabokke

et al. 2012

Journal of Pediatric Surgery

View full text Add to dashboard Cite

“…While early-stage tumors are treated effectively and may regress spontaneously, survival in patients with advanced-stage tumors is below 40% (2,3). Clinical heterogeneity and treatment morbidity (4,5) have driven the development of genetic and molecular screening approaches to identify children who may be spared intensive therapy (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Type III TGF-Î² receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma

Knelson¹,

Gaviglio²,

Tewari³

et al. 2013

J. Clin. Invest.

View full text Add to dashboard Cite

“…More than half of these patients have a metastatic disease at diagnosis. [1][2][3] NB cells disseminate either by hematogenous spread, producing metastasis most frequently in bone marrow, bone, liver, and skin, or by lymphatic spread to regional and distant lymph nodes. 4 Lung metastases are considered a terminal event representing a widely disseminated metastatic disease.…”

mentioning

confidence: 99%

Lung-Residing Metastatic and Dormant Neuroblastoma Cells

Botzer

Maman

Sagi‐Assif

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

The mechanism by which dormant tumor cells can begin growing after long periods of inactivity and accelerate disease recurrence is poorly understood. The present study characterizes dormant neuroblastoma (NB) cells, as well as metastatic cells, which reside in the same organ microenvironment. A xenograft model of human NB consisting of variants that generate nonmetastatic local tumors in the orthotopic inoculation site and variants that generate lung metastatic NB (MetNB) cells was developed in our laboratory. The present study shows that lungs of mice inoculated with nonmetastatic NB variants contain disseminated neuroblastoma (DisNB) human cells. Both DisNB and MetNB variants expressed a similar tumorigenicty phenotype in vivo, whereas the MetNB variants produced a heavy metastatic load and the DisNB variants produced no or little metastasis. A comparative in vitro characterization of MetNB and DisNB cells revealed similarities and differences. DisNB, but not MetNB cells, expressed the minimal residual disease markers PHOX2B and TH. MetNB cells demonstrated higher migratory capacity, an elevated matrix metalloproteinase (MMP) secretion, and a higher constitutive phosphorylation of extracellular signalregulated kinase (ERK) than DisNB cells. We suggest that characteristics common to both MetNB and DisNB cells were acquired relatively early in the metastatic process and the characteristics that differ between these variants were acquired later. We hypothesize that the DisNB cells are metastasis precursors, which may progress toward metastasis under certain microenvironmental conditions. Neuroblastoma (NB) is the most common extracranial solid tumor in children comprising 8% to 10% of all childhood cancers. More than half of these patients have a metastatic disease at diagnosis. 1-3 NB cells disseminate either by hematogenous spread, producing metastasis most frequently in bone marrow, bone, liver, and skin, or by lymphatic spread to regional and distant lymph nodes. 4 Lung metastases are considered a terminal event representing a widely disseminated metastatic disease. [5][6] Approximately 50% of children with high-risk NB that complete consolidation therapy develop early or late relapse, often from minimal residual disease in the form of circulating NB cells or micrometastases. 7 Most of the children with NB present metastatic disease at diagnosis with poor outcome, despite intensive treatment protocols. 8 The presence of circulating NB cells and/or NB micrometastasis may indicate a significant high-risk disease. 9 However, the question whether NB micrometastases develop into metastatic disease is yet to be answered.Previous studies from our laboratory were aimed to identify molecular pathways that are involved in NB metastasis. We focus on the cross talk between metastatic NB cells and components of their microenvironment, and on the downstream effects of such interactions.We suggested that NB cells might use chemokinechemokine receptor axes in their progression to metastasis. For example the CXCR4 -CXCL12 10 ...

show abstract

Neuroblastoma: contemporary management

Cited by 28 publications

References 91 publications

Minimally invasive adrenalectomy in children

Minimally invasive adrenalectomy in children

Type III TGF-Î² receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma

Lung-Residing Metastatic and Dormant Neuroblastoma Cells

Contact Info

Product

Resources

About